Cargando…

Parvovirus B19 in Croatia: A Large-Scale Seroprevalence Study

Background and Objectives: Seroepidemiological studies indicate that parvovirus B19 circulates in all areas of the world, although with some differences. The aim of this study is to analyze the seroprevalence of parvovirus B19 in the Croatian population. Materials and Methods: From 2010 to 2021, 153...

Descripción completa

Detalles Bibliográficos
Autores principales: Vilibic-Cavlek, Tatjana, Tabain, Irena, Kolaric, Branko, Mihulja, Klara, Blazevic, Lana, Bogdanic, Maja, Navolan, Dan, Beader, Natasa, Mrzljak, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8617724/
https://www.ncbi.nlm.nih.gov/pubmed/34833497
http://dx.doi.org/10.3390/medicina57111279
_version_ 1784604574797004800
author Vilibic-Cavlek, Tatjana
Tabain, Irena
Kolaric, Branko
Mihulja, Klara
Blazevic, Lana
Bogdanic, Maja
Navolan, Dan
Beader, Natasa
Mrzljak, Anna
author_facet Vilibic-Cavlek, Tatjana
Tabain, Irena
Kolaric, Branko
Mihulja, Klara
Blazevic, Lana
Bogdanic, Maja
Navolan, Dan
Beader, Natasa
Mrzljak, Anna
author_sort Vilibic-Cavlek, Tatjana
collection PubMed
description Background and Objectives: Seroepidemiological studies indicate that parvovirus B19 circulates in all areas of the world, although with some differences. The aim of this study is to analyze the seroprevalence of parvovirus B19 in the Croatian population. Materials and Methods: From 2010 to 2021, 1538 serum samples from different populations were tested for the presence of parvovirus B19 IgM/IgG antibodies. Serological tests were performed using a commercial enzyme-linked immunosorbent assay. Results: IgG antibodies were detected in 986/64.1% of participants with differences (p < 0.001) among the following population groups: 42.4% of children and adolescents, 67.1% of the adult general population, 66.7% of hemodialysis patients, and 65.6% of liver transplant recipients. Seroprevalence increased with age, from 30.0% in the 6 months–9 years age group to 69.0% in the 40–49 years age group, and remained stable thereafter (68.8–73.3%). There was no difference in the seropositivity among males (66.1%) and females (63.1%), as well as the place of residence (suburban/rural 63.9%, urban 64.1%). IgM antibodies (current/recent infection) were found in 61/4.0% of participants with the highest seropositivity in the youngest age group (11.1%). In pregnant women, seroprevalence was higher in women with an unfavorable obstetric history compared with a normal pregnancy (IgG 71.0% vs. 62.6%; IgM 6.5% vs. 2.4%), but these differences were not significant. Logistic regression showed that the adult population had almost three times higher risk of IgG seropositivity compared to children/adolescents (general population OR = 2.777, 95% CI = 2.023–3.812; hemodialysis patients OR = 2.586, 95% CI = 1.531–4.367; and transplant patients OR = 2.717, 95% CI = 1.604–4.603). A one-year increase in age increased the risk of IgG seroprevalence (OR = 1.017; 95% CI = 1.011–1.022). Conclusions: Older age was the main risk factor for IgG seropositivity. Hemodialysis and organ transplantation seem unrelated to the increased parvovirus B19 seroprevalence. The role of parvovirus B19 in the etiology of TORCH infections needs to be studied further.
format Online
Article
Text
id pubmed-8617724
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86177242021-11-27 Parvovirus B19 in Croatia: A Large-Scale Seroprevalence Study Vilibic-Cavlek, Tatjana Tabain, Irena Kolaric, Branko Mihulja, Klara Blazevic, Lana Bogdanic, Maja Navolan, Dan Beader, Natasa Mrzljak, Anna Medicina (Kaunas) Article Background and Objectives: Seroepidemiological studies indicate that parvovirus B19 circulates in all areas of the world, although with some differences. The aim of this study is to analyze the seroprevalence of parvovirus B19 in the Croatian population. Materials and Methods: From 2010 to 2021, 1538 serum samples from different populations were tested for the presence of parvovirus B19 IgM/IgG antibodies. Serological tests were performed using a commercial enzyme-linked immunosorbent assay. Results: IgG antibodies were detected in 986/64.1% of participants with differences (p < 0.001) among the following population groups: 42.4% of children and adolescents, 67.1% of the adult general population, 66.7% of hemodialysis patients, and 65.6% of liver transplant recipients. Seroprevalence increased with age, from 30.0% in the 6 months–9 years age group to 69.0% in the 40–49 years age group, and remained stable thereafter (68.8–73.3%). There was no difference in the seropositivity among males (66.1%) and females (63.1%), as well as the place of residence (suburban/rural 63.9%, urban 64.1%). IgM antibodies (current/recent infection) were found in 61/4.0% of participants with the highest seropositivity in the youngest age group (11.1%). In pregnant women, seroprevalence was higher in women with an unfavorable obstetric history compared with a normal pregnancy (IgG 71.0% vs. 62.6%; IgM 6.5% vs. 2.4%), but these differences were not significant. Logistic regression showed that the adult population had almost three times higher risk of IgG seropositivity compared to children/adolescents (general population OR = 2.777, 95% CI = 2.023–3.812; hemodialysis patients OR = 2.586, 95% CI = 1.531–4.367; and transplant patients OR = 2.717, 95% CI = 1.604–4.603). A one-year increase in age increased the risk of IgG seroprevalence (OR = 1.017; 95% CI = 1.011–1.022). Conclusions: Older age was the main risk factor for IgG seropositivity. Hemodialysis and organ transplantation seem unrelated to the increased parvovirus B19 seroprevalence. The role of parvovirus B19 in the etiology of TORCH infections needs to be studied further. MDPI 2021-11-21 /pmc/articles/PMC8617724/ /pubmed/34833497 http://dx.doi.org/10.3390/medicina57111279 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Vilibic-Cavlek, Tatjana
Tabain, Irena
Kolaric, Branko
Mihulja, Klara
Blazevic, Lana
Bogdanic, Maja
Navolan, Dan
Beader, Natasa
Mrzljak, Anna
Parvovirus B19 in Croatia: A Large-Scale Seroprevalence Study
title Parvovirus B19 in Croatia: A Large-Scale Seroprevalence Study
title_full Parvovirus B19 in Croatia: A Large-Scale Seroprevalence Study
title_fullStr Parvovirus B19 in Croatia: A Large-Scale Seroprevalence Study
title_full_unstemmed Parvovirus B19 in Croatia: A Large-Scale Seroprevalence Study
title_short Parvovirus B19 in Croatia: A Large-Scale Seroprevalence Study
title_sort parvovirus b19 in croatia: a large-scale seroprevalence study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8617724/
https://www.ncbi.nlm.nih.gov/pubmed/34833497
http://dx.doi.org/10.3390/medicina57111279
work_keys_str_mv AT vilibiccavlektatjana parvovirusb19incroatiaalargescaleseroprevalencestudy
AT tabainirena parvovirusb19incroatiaalargescaleseroprevalencestudy
AT kolaricbranko parvovirusb19incroatiaalargescaleseroprevalencestudy
AT mihuljaklara parvovirusb19incroatiaalargescaleseroprevalencestudy
AT blazeviclana parvovirusb19incroatiaalargescaleseroprevalencestudy
AT bogdanicmaja parvovirusb19incroatiaalargescaleseroprevalencestudy
AT navolandan parvovirusb19incroatiaalargescaleseroprevalencestudy
AT beadernatasa parvovirusb19incroatiaalargescaleseroprevalencestudy
AT mrzljakanna parvovirusb19incroatiaalargescaleseroprevalencestudy